


























































published: 23 June 2014
doi: 10.3389/fmed.2014.00018
Novel idea: virulence-based therapy against Helicobacter
pylori infection (smart therapy)
AminTalebi Bezmin Abadi*
Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands
*Correspondence: amin.talebi@gmail.com
Edited by:
YeongYeh Lee, Universiti Sains Malaysia, Malaysia
Reviewed by:
Katsunori Iijima, Tohoku University Graduate School of Medicine, Japan
Mohammad H. Derakhshan, University of Glasgow, UK
Keywords: Helicobacter pylori, virulence, smart therapy, novelty, treatment
INTRODUCTION
Helicobacter pylori (H. pylori) is a Gram-
negative, spiral, and microaerophilic bac-
terium, which can usually persist lifelong
in gastric mucosa if not treated efficiently.
H. pylori infection plays an undeniable role
in the development of different gastroduo-
denal diseases, while its eradication cures
ulcer disease and also prevents occurrence
of gastric cancer (1–3). At the beginning,
as usual, it was thought that antibacterial
therapy could easily eliminate the infection
in human gastric mucosa. As such, during
the last 30 years that we have known about
H. pylori, there have been numerous thera-
peutic regimens suggested (e.g., sequential,
triple/dual, quadruple, DANCE, hybrid,
salvage, and empirical) (4–8). Therefore,
many studies have been conducted to iden-
tify the most effective and least harmful
therapeutic regimen, although, a unique
therapeutic regimen to cureH. pylori infec-
tion in all reported colonized individuals
is still lacking (8, 9). However, high rates
of resistance have been reported to all pri-
mary/secondary lines and even to the newly
introduced alternative drugs described for
H. pylori treatment (10). In 2014, due to the
skyrocketing rates of antibiotics resistance,
a new scope toward the antibiotic therapy
against this mysterious bacterium seems
necessary. It has been indicated that vir-
ulence factors are the ability of a bacterium
to induce certain disease in attributed hosts
(1, 11, 12). Accordingly, virulence factors
in H. pylori (e.g., cagA, dupA, homB, and
vacA) have essential and definite roles in
pathogenesis of different gastroduodenal
disorders such as chronic gastritis, gastric
cancer, and peptic ulcers (13–15). Certain
H. pylori strains (specific PCR positive for
cagA, dupA, homB, and vacA) harboring
virulence determinants are capable to sur-
vive longer and induce more severe dis-
eases. Surprisingly, among the currently
described studies, no therapeutic regimen
according to H. pylori virulence pattern
(virutype) has yet been suggested.
PROPOSED IDEA
Given the aforementioned problems in
H. pylori treatment, it would be interest-
ing if new therapeutic approaches can solve
this complexity. Accordingly, under condi-
tion of smart therapy, we propose an idea
that suggests logical application of smart
therapy against H. pylori strains that will
reduce current distribution of antibiotic
resistance and also increase efficacy of pre-
scribed antibiotics. If a clinician knows
about virutype and susceptibility pattern
of H. pylori locally, it is easy to choose a
therapeutic regimen (smart therapy) that
will reliably cure most of infections during
the first-line therapy. In clinical settings,
by prescription of smart therapy, physi-
cians can opt to not treat non-virulent
strains found in symptomatic patients,
which account for more than half of all sub-
jects. If smart therapy is validated as a new
therapeutic regimen, current therapeutic
failures will be considerably reduced.
EVALUATION OF THE IDEA
In order to have a continuing effective
therapeutic regimen against H. pylori, we
practically suggest to first investigating vir-
ulence pattern (virutype) of the bacterium,
therefore; antibiotic therapy should be con-
sidered only for virulent strains (smart
therapy). Clinicians should only aim to
detect virulent H. pylori according to the
virulence genes, and then start to eradicate
them based on local antibiotic suscepti-
bility pattern. Indeed, detection of such
virulent strains (vacA+, cagA+, homB+,
and dupA+), identified by the simple sen-
sitive PCR method, can be the main inclu-
sion criteria to start the next step. If so,
as the second step (in the case of viru-
lent H. pylori strain), we need to follow
an updated antibiotic susceptibility profile,
which indicates the most effective drugs for
each region.
DISCUSSION/CONCLUSION
Helicobacter pylori is inherently resistant
to a few antibiotics (e.g., sulfonamides,
trimethoprim, nalidixic acid, and van-
comycin), and it will likely become resistant
to metronidazole, clarithromycin, and flu-
oroquinolones, if these antibiotics are pre-
scribed alone (16, 17). Given the significant
presence of virulence factors in H. pylori
pathogenesis and the direct link to cause
more severe diseases, it is hypothesized that
designation of therapeutic regimen accord-
ing to virulence factors may help physicians
to increase efficacy rate of therapy (18).
The smart therapy strategy consists of two
basic parts; (i) local antibiotic susceptibility
tests and (ii) H. pylori virutype. The main
advantage of smart therapy is its flexibil-
ity, which can give the possibility to clini-
cians for adjusting new antibiotics accord-
ing to different localities in the world. As we
already knew, antibiotic exposure is one of
the main factors, which can push H. pylori
to make new mutations, and can eventu-
ally result in more resistant genotypes. In
essence, smart therapy can avoid from dis-
tribution of antibiotic resistance due to
careful usage of its contained drugs for
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therapeutic regimens. Within smart ther-
apy, the answer to the question of how
resistant strains should be eradicated is to
logically target virulent strains and smartly
tackle those using effective combinations
of antibiotics. We therefore conclude that
our idea can enable the possible applica-
tion of smart therapy in clinical practice for
symptomatic digestive diseases. According
to the smart therapy, more studies of pre-
scribed drugs and certain virulence genes
are suggested to examine their potential to
be incorporated as virutypes of H. pylori.
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